211 related articles for article (PubMed ID: 4038381)
21. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
22. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
Goddard P; Valenti M; Kelland LR
Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives.
Moebus VJ; Stein R; Kieback DG; Runnebaum IB; Sass G; Kreienberg R
Anticancer Res; 1997; 17(2A):815-21. PubMed ID: 9137413
[TBL] [Abstract][Full Text] [Related]
24. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.
Bernacki RJ; Oberman EJ; Seweryniak KE; Atwood A; Bergeron RJ; Porter CW
Clin Cancer Res; 1995 Aug; 1(8):847-57. PubMed ID: 9816054
[TBL] [Abstract][Full Text] [Related]
25. Response of nude mouse-grown adenocarcinomas of the human exocrine pancreas to cis-diamminedichloroplatinum(II), diammine[1,1-cyclobutanedicarboxylato(2-)-O,O'-platinum], and mitoguazone dihydrochloride.
Kyriazis AP; Kyriazis AA; Yagoda A; Fogh J
Cancer Res; 1985 Sep; 45(9):4354-9. PubMed ID: 3896479
[TBL] [Abstract][Full Text] [Related]
26. Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.
van Hennik MB; van der Vijgh WJ; Klein I; Elferink F; Vermorken JB; Winograd B; Pinedo HM
Cancer Res; 1987 Dec; 47(23):6297-301. PubMed ID: 3315183
[TBL] [Abstract][Full Text] [Related]
27. Initiatives with platinum- and quinazoline-based antitumor molecules--Fourteenth Bruce F. Cain Memorial Award Lecture.
Harrap KR
Cancer Res; 1995 Jul; 55(13):2761-8. PubMed ID: 7796401
[TBL] [Abstract][Full Text] [Related]
28. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
[TBL] [Abstract][Full Text] [Related]
29. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
30. Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice.
Boven E; Nauta MM; Schluper HM; Elferink F; van der Vijgh WJ; Pinedo HM
Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1253-60. PubMed ID: 4076289
[TBL] [Abstract][Full Text] [Related]
31. Response of nude mouse-grown human urothelial cancer to cis-diamminedichloroplatinum(II), diammine[1,1-cyclobutanedicarboxylato(2-)-O,O'-platinum], and mitoguazone dihydrochloride.
Kyriazis AP; Yagoda A; Kyriazis AA; Fogh J
Cancer Res; 1985 May; 45(5):2012-5. PubMed ID: 3886128
[TBL] [Abstract][Full Text] [Related]
32. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of platinol analogs using the M5076 murine sarcoma.
Rose WC
Anticancer Res; 1986; 6(4):557-62. PubMed ID: 3530116
[TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo.
Welters MJ; Fichtinger-Schepman AM; Baan RA; Jacobs-Bergmans AJ; Kegel A; van der Vijgh WJ; Braakhuis BJ
Br J Cancer; 1999 Jan; 79(1):82-8. PubMed ID: 10408697
[TBL] [Abstract][Full Text] [Related]
35. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
Li D; Williams JI; Pietras RJ
Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
[TBL] [Abstract][Full Text] [Related]
36. Comparative effect of cisplatin, spiroplatin, carboplatin and iproplatin in a human tumor clonogenic assay.
Schroyens W; Dodion P; Rozencweig M
J Cancer Res Clin Oncol; 1990; 116(4):392-6. PubMed ID: 2202731
[TBL] [Abstract][Full Text] [Related]
37. Enhancement of antineoplastic effects of cisplatin by a calmodulin antagonist (W-7) in nude mice bearing human ovarian carcinoma.
Oomori K; Kikuchi Y; Kita T; Iwano I; Kizawa I; Kato K
Cancer Detect Prev; 1988; 12(1-6):481-6. PubMed ID: 3180142
[TBL] [Abstract][Full Text] [Related]
38. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
[TBL] [Abstract][Full Text] [Related]
39. [Antitumor activity and toxicity of KB-5424 R, a newly developed antitumor platinum compound].
Yamaguchi H; Kubota T; Takahara T; Takeuchi T; Furukawa T; Kase S; Josui K; Kodaira S; Ishibiki K; Abe O
Gan To Kagaku Ryoho; 1991 Jun; 18(7):1135-41. PubMed ID: 2053772
[TBL] [Abstract][Full Text] [Related]
40. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
